These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 3283413)

  • 21. Five years' experience of combination therapy: peritoneal dialysis with hemodialysis.
    Kawanishi H; Moriishi M; Tsuchiya S
    Adv Perit Dial; 2002; 18():62-7. PubMed ID: 12402589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KT/V: the denominator dilemma.
    Lindholm B; Waniewski J; Weryński A
    Pol Merkur Lekarski; 2003 Oct; 15(88):311-5. PubMed ID: 14974355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The equivalent renal urea clearance: a new parameter to assess dialysis dose.
    Casino FG; Lopez T
    Nephrol Dial Transplant; 1996 Aug; 11(8):1574-81. PubMed ID: 8856214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Renal replacement therapy by hemodialysis: an overview].
    Jacobs C
    Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dialysis adequacy and nutritional status of hemodialysis patients.
    Teixeira Nunes F; de Campos G; Xavier de Paula SM; Merhi VA; Portero-McLellan KC; da Motta DG; de Oliveira MR
    Hemodial Int; 2008 Jan; 12(1):45-51. PubMed ID: 18271840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adequacy and nutrition in the absence of residual renal function in peritoneal dialysis.
    Canale R; Barone RJ; Gimenez NS; Santopietro M; Ramirez L; Palliotti A; Romero P; Amado D
    Adv Perit Dial; 2001; 17():230-4. PubMed ID: 11510282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Which mathematical model to study uremic toxicity? National Cooperative Dialysis Study.
    Sargent JA; Lowrie EG
    Clin Nephrol; 1982 Jun; 17(6):303-14. PubMed ID: 7049475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous measurement of DTPA-clearance in extracorporeal detoxification circuits.
    Falkenhagen D; Ahrenholz P; Roy T; Esther G; Kiencke H; Klinkmann H
    Artif Organs; 1981; 4 Suppl():166-8. PubMed ID: 7295085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nitrogen balance studies and Kt/V urea in children undergoing chronic peritoneal dialysis.
    Cano FJ; Azocar MA; Delucchi MA; Rodriguez EE; Marin VS; Diaz ED; Mazuel N
    Adv Perit Dial; 2004; 20():245-50. PubMed ID: 15384835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small-solute and middle-molecule clearances during continuous flow peritoneal dialysis.
    Leypoldt JK; Burkart JM
    Adv Perit Dial; 2002; 18():26-31. PubMed ID: 12402582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adequacy of CPD: comparing Kt/V and creatinine clearance.
    Juergensen PH; Allen JR; Kliger AS; Finkelstein FO
    Adv Perit Dial; 1998; 14():72-4. PubMed ID: 10649695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once upon a time in dialysis: the last days of Kt/V?
    Vanholder R; Glorieux G; Eloot S
    Kidney Int; 2015 Sep; 88(3):460-5. PubMed ID: 26061543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peritoneal dialysis clearances. A practical approach to the measurement of small- and middle-molecule clearances.
    Brown EA; Kliger AS; Finkelstein FO
    Nephron; 1978; 21(6):310-6. PubMed ID: 714202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K; Kidawa Z; Walasek L; Lutz W
    Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
    [No Abstract]   [Full Text] [Related]  

  • 36. Our experience with combined hemodialysis-hemoperfusion treatment in chronic uremia.
    Splendiani G; Albano V; Tancredi M; Daniele M; Pignatelli F
    Biomater Artif Cells Artif Organs; 1987; 15(1):175-81. PubMed ID: 3449135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival of hemodialysis patients and uremic toxin removal.
    Vanholder R; Smet RD; Glorieux G; Dhondt A
    Artif Organs; 2003 Mar; 27(3):218-23. PubMed ID: 12662205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of chromatographic fractions of blood ultrafiltrates of patients with chronic uremia on the fibrinolytic activity]].
    Popławski A; Myśliwiec M; Soszka J
    Pol Tyg Lek; 1990 Oct 1-8; 45(40-41):810-3. PubMed ID: 2096374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electroencephalographic and other neurophysiological abnormalities in uremia.
    Teschan PE
    Kidney Int Suppl; 1975 Jan; (2):210-6. PubMed ID: 1057681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Critical evaluation of dialytic adequacy].
    Ghezzi PM
    Minerva Urol Nefrol; 1991; 43(3):191-200. PubMed ID: 1817344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.